rs753806542
Variant summary
Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PM3
This summary comes from the ClinGen Evidence Repository: The c.590G>A variant in ATM is a missense variant predicted to cause substitution of glycine by glutamic acid at amino acid 197 (p.Gly197Glu). This variant has been detected in at least two individuals with Ataxia-Telangiectasia (PMID:18846412, 26896183). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0002288 in the South Asian population (PM2_Supporting, BS1, and BA1 are not met). The computational predictor REVEL gives a score of 0.66, which is neither above nor below the thresholds predicting a damaging or benign impact on ATM function. In summary, this variant meets criteria to be classified as a variant of uncertain significance for autosomal dominant ATM-related cancer predisposition and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied as specified by the HBOP Variant Curation Expert Panel. (PM3) LINK:https://erepo.genome.network/evrepo/ui/classification/CA6264634/MONDO:0700270/020
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary breast carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: Ambry Genetics, ClinGen
- ataxia telangiectasiaInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P, ClinGen, Laboratory for Molecular Medicine, Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: MODERATE, LIMITED Submitted by: ClinGen, Ambry Genetics
- prostate cancerInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- sarcomaInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- familial ovarian cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
- gastric carcinomaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ATM | NM_000051.4 | c.590G>A | p.Gly197Glu | missense_variant | Exon 6 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 151912Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000279 AC: 7AN: 250934 AF XY: 0.0000442 show subpopulations
GnomAD4 exome AF: 0.0000123 AC: 18AN: 1461462Hom.: 0 Cov.: 34 AF XY: 0.0000165 AC XY: 12AN XY: 727012 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000658 AC: 1AN: 151912Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74184 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Familial cancer of breast Pathogenic:1Uncertain:2
This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 197 of the ATM protein (p.Gly197Glu). This amino acid position is highly conserved. This variant is present in population databases (rs753806542, gnomAD 0.02%). This missense change has been observed in individual(s) with atypical ataxia-telangiectasia (PMID: 18846412). ClinVar contains an entry for this variant (Variation ID: 420008). In addition, this alteration is predicted to be deleterious by in silico analysis. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
This variant is considered likely pathogenic. This variant is expected to disrupt protein structure [Myriad internal data]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 18846412, 37438524, 39138584, 30283815]. -
- -
Ataxia-telangiectasia syndrome Pathogenic:1Uncertain:1
This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 197 of the ATM protein (p.Gly197Glu). This variant is present in population databases (rs753806542, gnomAD 0.02%). This missense change has been observed in individual(s) with atypical ataxia-telangiectasia (PMID: 18846412). ClinVar contains an entry for this variant (Variation ID: 420008). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects ATM function (PMID: 18846412). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
A homozygous missense variation in exon 6 of the ATM gene that results in the amino acid substitution of Glutamic acid for Glycine at codon 197 was detected. The observed variant c.590G>A (p.Gly197Glu) has not been reported in the 1000 genomes and gnomAD database. The in silico prediction of the variant are probably damaging by PolyPhen-2 and damaging by SIFT, MutationTaster2 and LRT. The reference codon is conserved across species. In summary, the variant meets our criteria to be classified as a likely pathogenic variant. -
ATM-related cancer predisposition Uncertain:2
The c.590G>A variant in ATM is a missense variant predicted to cause substitution of glycine by glutamic acid at amino acid 197 (p.Gly197Glu). This variant has been detected in at least two individuals with Ataxia-Telangiectasia (PMID: 18846412, 26896183). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0002288 in the South Asian population (PM2_Supporting, BS1, and BA1 are not met). The computational predictor REVEL gives a score of 0.66, which is neither above nor below the thresholds predicting a damaging or benign impact on ATM function. In summary, this variant meets criteria to be classified as a variant of uncertain significance for autosomal dominant ATM-related cancer predisposition and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied as specified by the HBOP Variant Curation Expert Panel. (PM3) -
- -
not provided Uncertain:2
Observed as apparently homozygous in an individual with a pharyngeal telangiectasia and dystonia with onset at 15 years old and in two consanguineous siblings with ataxia, global developmental delay, and hypotonia (PMID: 18846412, 30283815, 30549301); Published functional studies are inconclusive: reduced ATM protein levels but retained kinase activity (PMID: 18846412); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 23143971, 25040471, 28779002, 30283815, 30549301, 36293153, 37438524, 35585550, 26896183, 18846412) -
The ATM c.590G>A (p.Gly197Glu) variant has been reported in the published literature in individuals with ataxia telangiectasia (PMID: 26896183 (2016), 18846412 (2009)) and a reportedly healthy individual (PMID: 28779002 (2017)). Functional studies demonstrated that this variant has an inconclusive effect on protein function (PMID: 18846412 (2009)). The frequency of this variant in the general population, 0.00023 (7/30596 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Hereditary cancer-predisposing syndrome Uncertain:2
This missense variant replaces glycine with glutamic acid at codon 197 of the ATM protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). This variant has been reported in homozygosity in an individual affected with a mild form of ataxia telangiectasia (PMID: 18846412). A lymphoblastoid cell line derived from this pronand showed a partially reduced ATM protein expression and kinase activity (PMID: 18846412). This variant has been observed in an healthy control individual in a breast cancer case-control study (PMID 28779002). This variant has been identified in 7/250934 chromosomes (7/30596 South Asian chromosomes) in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in hereditary cancer conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.G197E variant (also known as c.590G>A), located in coding exon 5 of the ATM gene, results from a G to A substitution at nucleotide position 590. The glycine at codon 197 is replaced by glutamic acid, an amino acid with similar properties. This alteration has been reported as homozygous in a patient with atypical ataxia-telangiectasia (A-T) whose primary presentation was dystonia at age 15 years (Carrillo F et al. Cerebellum. 2009 Mar;8(1):22-7). A lymphoblastoid cell line derived from the patient's blood showed a reduced level of ATM protein; the ATM protein retained some kinase activity in vivo. This alteration has also been reported as homozygous in two siblings who presented with global developmental delay and ataxia (Cordeiro D et al. Neurol Genet, 2018 Oct;4:e265). Additionally, this alteration was identified in the homozygous state in an individual with a clinical diagnosis of of A-T (Kim J et al. Nature, 2023 Jul;619:828-836). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at